Irinotecan oral - Hanmi Pharmaceutical

Drug Profile

Irinotecan oral - Hanmi Pharmaceutical

Alternative Names: Irinotecan + HM 30181A; Oral irinotecan - Hanmi Pharmaceutical; Oratecan

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules; Vinca alkaloids
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Colorectal cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Tablet)
  • 27 Jan 2017 PharmaEssentia acquires the rights to develop and commercialise irinotecan oral (Oratecan) in Vietnam (9213637; 9213921)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in South Korea (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top